Amicogen, Inc. (092040.KQ)
KRW 3930.0
(-3.2%)
KRW 3930.0
(-3.2%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 51.51 Billion KRW | 21.22% |
| 2022 | 42.49 Billion KRW | 1.62% |
| 2021 | 41.81 Billion KRW | 0.33% |
| 2020 | 41.67 Billion KRW | -8.81% |
| 2019 | 45.7 Billion KRW | 56.27% |
| 2018 | 29.24 Billion KRW | 23.19% |
| 2017 | 23.74 Billion KRW | 2.2% |
| 2016 | 23.23 Billion KRW | 97.64% |
| 2015 | 11.75 Billion KRW | -14.19% |
| 2014 | 13.69 Billion KRW | 15.17% |
| 2013 | 11.89 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 11.5 Billion KRW | 22.59% |
| 2024 Q1 | 9.38 Billion KRW | -26.21% |
| 2023 FY | 51.51 Billion KRW | 21.22% |
| 2023 Q3 | 13.35 Billion KRW | -2.86% |
| 2023 Q1 | 11.69 Billion KRW | -10.19% |
| 2023 Q4 | 12.71 Billion KRW | -4.74% |
| 2023 Q2 | 13.74 Billion KRW | 17.52% |
| 2022 Q4 | 13.02 Billion KRW | 11.21% |
| 2022 FY | 42.49 Billion KRW | 1.62% |
| 2022 Q3 | 11.71 Billion KRW | 31.05% |
| 2022 Q2 | 8.93 Billion KRW | 1.25% |
| 2022 Q1 | 8.82 Billion KRW | -22.47% |
| 2021 FY | 41.81 Billion KRW | 0.33% |
| 2021 Q4 | 11.38 Billion KRW | 46.04% |
| 2021 Q2 | 11.22 Billion KRW | -1.66% |
| 2021 Q1 | 11.41 Billion KRW | -7.06% |
| 2021 Q3 | 7.79 Billion KRW | -30.55% |
| 2020 FY | 41.67 Billion KRW | -8.81% |
| 2020 Q1 | 10.11 Billion KRW | -58.08% |
| 2020 Q2 | 11.64 Billion KRW | 15.1% |
| 2020 Q3 | 10.5 Billion KRW | -9.79% |
| 2020 Q4 | 12.28 Billion KRW | 16.9% |
| 2019 Q3 | 7.18 Billion KRW | -20.62% |
| 2019 Q1 | 7.85 Billion KRW | 35.8% |
| 2019 FY | 45.7 Billion KRW | 56.27% |
| 2019 Q4 | 24.13 Billion KRW | 235.91% |
| 2019 Q2 | 9.05 Billion KRW | 15.16% |
| 2018 Q2 | 8 Billion KRW | -3.54% |
| 2018 FY | 29.24 Billion KRW | 23.19% |
| 2018 Q4 | 5.78 Billion KRW | -28.67% |
| 2018 Q3 | 8.11 Billion KRW | 1.38% |
| 2018 Q1 | 8.29 Billion KRW | -4.9% |
| 2017 FY | 23.74 Billion KRW | 2.2% |
| 2017 Q1 | 6.15 Billion KRW | -27.93% |
| 2017 Q2 | 5.77 Billion KRW | -6.04% |
| 2017 Q3 | 3.87 Billion KRW | -32.97% |
| 2017 Q4 | 8.72 Billion KRW | 125.26% |
| 2016 FY | 23.23 Billion KRW | 97.64% |
| 2016 Q4 | 8.53 Billion KRW | 192.18% |
| 2016 Q3 | 2.92 Billion KRW | -31.37% |
| 2016 Q2 | 4.25 Billion KRW | -45.62% |
| 2016 Q1 | 7.82 Billion KRW | 15.54% |
| 2015 Q3 | 564.62 Million KRW | -77.29% |
| 2015 Q2 | 2.48 Billion KRW | 41.67% |
| 2015 Q1 | 1.75 Billion KRW | -72.36% |
| 2015 FY | 11.75 Billion KRW | -14.19% |
| 2015 Q4 | 6.77 Billion KRW | 1099.88% |
| 2014 Q2 | 2.35 Billion KRW | -10.31% |
| 2014 Q1 | 2.62 Billion KRW | -34.23% |
| 2014 Q3 | 2.35 Billion KRW | 0.06% |
| 2014 Q4 | 6.35 Billion KRW | 169.18% |
| 2014 FY | 13.69 Billion KRW | 15.17% |
| 2013 Q4 | 3.99 Billion KRW | 162.42% |
| 2013 FY | 11.89 Billion KRW | 0.0% |
| 2013 Q2 | 3.6 Billion KRW | 25.5% |
| 2013 Q3 | 1.52 Billion KRW | -57.73% |
| 2013 Q1 | 2.87 Billion KRW | 0.0% |
| 2012 Q3 | 1.42 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| HLB Co., Ltd. | -6.01 Billion KRW | 956.765% |
| iNtRON Biotechnology, Inc. | 4.56 Billion KRW | -1029.451% |
| BINEX Co., Ltd. | 56.65 Billion KRW | 9.077% |
| Bioneer Corporation | 199.25 Billion KRW | 74.147% |
| Anterogen.Co.,Ltd. | 2.21 Billion KRW | -2227.274% |
| MEDIPOST Co., Ltd. | 40.18 Billion KRW | -28.192% |
| CrystalGenomics, Inc. | 1.45 Billion KRW | -3435.527% |
| Helixmith Co., Ltd | 2.12 Billion KRW | -2327.73% |
| Chabiotech Co.,Ltd. | 255.19 Billion KRW | 79.814% |
| Medy-Tox Inc. | 128.16 Billion KRW | 59.806% |
| Peptron, Inc. | 1.14 Billion KRW | -4416.374% |
| Genexine, Inc. | 387.48 Million KRW | -13194.151% |
| HLB Therapeutics Co.,Ltd. | 6.69 Billion KRW | -669.508% |
| LegoChem Biosciences, Inc. | 17.79 Billion KRW | -189.442% |
| ALTEOGEN Inc. | 31.19 Billion KRW | -65.113% |
| PharmaResearch Co., Ltd. | 182.25 Billion KRW | 71.736% |
| SillaJen, Inc. | 1.45 Billion KRW | -3436.164% |
| JETEMA, Co., Ltd. | 26.58 Billion KRW | -93.789% |
| OliX Pharmaceuticals,Inc | 14.42 Billion KRW | -257.174% |
| Genomictree Inc. | -1.03 Billion KRW | 5059.863% |
| MedPacto, Inc. | -1.83 Billion KRW | 2910.814% |
| D&D Pharmatech | 18.67 Billion KRW | -175.808% |
| EASY BIO,Inc. | 50.88 Billion KRW | -1.232% |
| GI Innovation, Inc. | 1.98 Billion KRW | -2489.334% |